Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia

Infections represent one of the most frequent complications during the treatment of patients with Acute Lymphoblastic Leukemia (ALL): of these, almost half develop an infectious event in the majority of cases in induction. The new monoclonal and bispecific antibodies and CAR-T, besides offering new perspectives in the overall survival and disease-free survival of patients, may also transform the epidemiology of infections in ALL by improving the toxicity of treatments. In this review, we examined studies published in the literature over the past 12 years and described the infectious complications of therapy with Blinatumomab, Inotuzumab, Rituximab and CAR-T in adult and pediatric patients with ALL. Infections are less frequent than in traditional chemotherapy treatment with vincristine, corticosteroids and anthracyclines, which has been the backbone of therapy for patients with ALL for years. On the other hand, the infection scenario in the CAR-T setting is quite peculiar: In these patients, infections are more frequent in the first month after infusion and are predominantly bacterial. As the time moves away from day zero, viral infections become more frequent, occurring mainly in patients who have had prolonged cytopenia and major cytokine release syndrome.

Automated summary

Infections are common complications during the treatment of Acute Lymphoblastic Leukemia (ALL), with almost half of the patients developing infectious events during induction. The use of new monoclonal and bispecific antibodies and CAR-T therapy has the potential to improve overall survival and disease-free survival of patients with ALL and may also impact the epidemiology of infections in this population. This review focused on the infectious complications of Blinatumomab, Inotuzumab, Rituximab, and CAR-T therapy in both adult and pediatric ALL patients, highlighting the unique infection patterns observed in CAR-T patients.